Cambridge’s Dimension Therapeutics Preps for $115 Million IPO

Published: Sep 15, 2015

Dimension Therapeutics, which is developing novel, liver-directed gene therapies for rare genetic disorders, filed on Monday with the SEC to raise up to $115 million in an initial public offering.

Dimension Therapeutics licenses its AAV vector gene delivery technology from REGENXBIO (RGNX), which is on the IPO calendar to raise $100 million this week.

Help employers find you! Check out all the jobs and post your resume.

Back to news